Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study

European Journal of Cancer

Volumn 32, Issue 2, 1996, Pages 243-248

  Gatzemeier, U ^f   Shepherd, F A ^f   Le Chevalier, T ^f   Weynants, P ^f   Cottier, B ^f   Groen, H J M ^f   Rosso, R ^a   Mattson, K ^f   Cortes Funes, H ^b   Tonato, M ^c   Burkes, R L ^d   Gottfried, M ^f   Voi, M ^e  

^a UNIVERSITY OF GENOA   (Italy)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c Ospedale Regionale   (Italy)

^d MOUNT SINAI HOSPITAL   (Canada)

^e ELI LILLY AND COMPANY   (United States)

^f NONE

Author keywords

Chemotherapy; Gemcitabine; Non small cell lung cancer

Indexed keywords

GEMCITABINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TIME FACTORS;

EID: 0029914387     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00444-0     Document Type: Article

References (33)

1. Kris M, Cohen E, Gralla R. An analysis of 134 phase II trials in non-small cell lung cancer (NSCLC). World Conference on Lung Cancer 1986, 2, 115.
2. Itri L, Gralla R. A review of etoposide in patients with non-small cell lung cancer (NSCLC). Cancer Treat Rev 1982, 9, 115-118.
3. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung In DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology, Fourth Edition. Philadelphia, JB Lippincott & Co, 1993, 673-723.
4. Huang P, Chubb S, Hertel L, et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51, 6110-6117.
5. Plunkett W, Gandhi V, Chubb S, et al. 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukaemia cells. Nucleosides Nucleotides 1989, 8, 775-785.
6. Xu Y-Z, Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1992, 44, 1819-1827.
7. Heinemann V, Hertel LW, Grindey GB, et al. Comparison of the cellular pharmacokinetics and toxicity of 2′-2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988, 48, 4024-4031.
8. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the anti-tumor activity of gemcitabine, (difluoro-2′-deoxycytidine). Cancer Res 1990, 50, 4417-4422.
9. Braakhuis BJM, Van Dongen GAMS, Vermorken JB, et al. Pre-clinical in vivo activity of 2′, 2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991, 51, 211-214.
10. Fujita M, Fujita F, Inabah H, et al. Investigations of anti-tumor effects of LY 188011 (gemcitabine) against human cancer xenografts in nude mice. Jpn J Cancer Chemother 1994, 21, 517-523.
11. Schultz RM, Merriman RL, Toth JE, et al. Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncology Res 1993, 5, 223-228.
12. O'Rourke TJ, Brown TD, Havlin K, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer 1994, 30, 417-418.
13. Poplin E, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC) - gemcitabine: a phase I study. Invest New Drugs 1992, 10, 165-170.
14. Tanis B, Clavel M, Guastalla J, et al. Phase I study of gemcitabine (difluorodeoxycytidine, dFdC (LY188011)) administered in a two-weekly schedule. Proc Am Assoc Cancer Res 1990, 31, 1239.
15. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991, 9, 491-498.
16. Abratt R, Bezwoda W, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12, 1535-1540.
17. Anderson H, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994, 12, 1821-1826.
18. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst 1994, 86, 1530-1533.
19. Carmichael J, Possinger K, Philip P, et al. Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. Proc Am Soc Clin Oncol 1993, 12, 64.
20. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 1994, 5, 283-285.
21. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from phase I study. Ann Oncol 1994, 5, 182-184.
22. Beahrs OH, Henson DE, Hutter RVP, et al. American Joint Committee on Cancer, eds. Manual for Staging of Cancer, Fourth Edition. Philadelphia, JB Lippincott, 1992.
23. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organisation, 1979.
24. Depierre A, Lemarie E, Dabouis G, et al. A phase II study of Navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol (CCT) 1991, 14, 115-119.
25. Fernandez O, Bruno J, Mickiewicz E, et al. Randomized comparison of navelbine (NVB) and cisplatin (CDDP) versus navelbine alone in patients with inoperable non-small cell lung cancer (NSCLC). Proc 15th Int Cancer Congr J Cancer Res Clin Oncol 1990, V 116 Suppl.
26. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994, 12, 360-367.
27. Souhami RL, Rudd RM, Spiro SG, et al. Phase II study of edatrexate in stage III and IV non-small cell lung cancer. Cancer Chemother Pharmacol 1992, 30, 465-468.
28. Lee JS, Libshitz HI, Murphy WK, et al. Phase II study of 10-ethyl-10-deaza-aminopterin (10EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer. Invest New Drugs 1990, 8, 299-304.
29. Shum KY, Kris MG, Gralla RJ, et al. Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1988, 6, 446-450.
30. Chang AY, Kim K, Click J, et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993, 85, 388-394.
31. Murphy WK, Fosella FV, Winn RJ, et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993, 85, 384-388.
32. Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992, 10, 16-20.
33. Wils J, Utama I, Sala L, et al. Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer 1990, 26, 1140-1141.